Business

Novo Nordisk Loses GLP-1 Weight-Loss Drug Market Lead

Updated 2026-08-05 17:10 UTC 1 source Negative

Novo Nordisk, the maker of Ozempic, lost its lead in the GLP-1 weight-loss drug market to Eli Lilly. The Danish company developed the most lucrative new drug but was outmaneuvered by its competitor.

Coverage timeline — 1 article

MarketWatch

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

2026-08-05 16:52 UTC